Sol-Gel Technologies - SLGL Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sol-Gel Technologies in the last twelve months. There are currently 1 hold rating, 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SLGL shares.
View SLGL analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 1-year price targets for Sol-Gel Technologies' shares. Their SLGL share price forecasts range from $5.50 to $19.00. On average, they anticipate the company's stock price to reach $11.50 in the next twelve months. This suggests a possible upside of 233.3% from the stock's current price.
View analysts price targets for SLGL or view top-rated stocks among Wall Street analysts.

Sol-Gel Technologies' stock was trading at $4.5599 at the beginning of the year. Since then, SLGL stock has decreased by 24.3% and is now trading at $3.45.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Friday, May 12th 2023.
View our SLGL earnings forecast.

Sol-Gel Technologies Ltd. (NASDAQ:SLGL) posted its earnings results on Thursday, November, 11th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.08) by $0.13. The business had revenue of $8.84 million for the quarter, compared to the consensus estimate of $9.53 million. Sol-Gel Technologies had a negative net margin of 384.42% and a negative trailing twelve-month return on equity of 31.39%.

Invesco Raymond James SB-1 Equity ETF holds 7,985 shares of SLGL stock, representing 0.02% of its portfolio.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sol-Gel Technologies investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Flexion Therapeutics (FLXN), Iovance Biotherapeutics (IOVA), Marker Therapeutics (MRKR), Teva Pharmaceutical Industries (TEVA), Viking Therapeutics (VKTX), Verona Pharma (VRNA) and Adaptimmune Therapeutics (ADAP).

(SLGL) raised $60 million in an initial public offering (IPO) on Thursday, February 1st 2018. The company issued 5,000,000 shares at $11.00-$13.00 per share. ​Jefferies and BMO Capital Markets​ served as the underwriters for the IPO and JMP Securities and Raymond James​ were co-managers.

Sol-Gel Technologies trades on the NASDAQ under the ticker symbol "SLGL."

Sol-Gel Technologies' stock is owned by many different retail and institutional investors. Top institutional investors include Raymond James Financial Services Advisors Inc. (0.21%), Raymond James & Associates (0.14%), Morgan Stanley (0.13%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

Shares of SLGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SLGL stock can currently be purchased for approximately $3.45.

Sol-Gel Technologies (NASDAQ:SLGL) has a market capitalization of $79.80 million and generates $3.88 million in revenue each year. The company earns $-14,920,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.

Sol-Gel Technologies' mailing address is 7 GOLDA MEIR ST. WEIZMANN SCIENCE PARK, NESS ZIONA L3, 7403648. The official website for the company is www.sol-gel.com. The company can be reached via phone at (728) 931-3433, via email at crusso@soleburytrout.com, or via fax at 972-153-523044444.